OS estimates according to randomization and ELN genetic group.⁵  (A) Favorable and intermediate I/II groups. Median OS times for patients who received LDAC (n = 28) and LDAC + volasertib (n = 22) were 7.8 and 9.8 months, respectively (HR, 0.54; 95% CI 0.29-1.02). (B) Adverse group. Median OS times for patients who received LDAC (n = 14) and LDAC + volasertib (n = 14) were 3.3 and 5.9 months, respectively (HR, 0.63; 95% CI, 0.29-1.40). Database snapshot November 7, 2013.